While removal of DNA methylation results in transcriptional activation in only few genes, the upregulation of both TET2 and PAX5 after demethylation by GSK5032, as seen here, indicates that T-ALL patients with a hypermethylated phenotype could benefit from treatment with HMAs. The gene discussed is TET2; the disease is acute lymphoblastic leukemia.